➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
McKesson
Harvard Business School
Medtronic
Dow

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

SODIUM PENTOBARBITAL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Sodium Pentobarbital, and when can generic versions of Sodium Pentobarbital launch?

Sodium Pentobarbital is a drug marketed by Anabolic, Elkins Sinn, Everylife, Halsey, Ivax Sub Teva Pharms, Parke Davis, Perrigo, Purepac Pharm, Valeant Pharm Intl, Watson Labs, Wyeth Ayerst, and Nexgen Pharma Inc. and is included in thirteen NDAs.

The generic ingredient in SODIUM PENTOBARBITAL is pentobarbital sodium. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pentobarbital sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Sodium Pentobarbital

A generic version of SODIUM PENTOBARBITAL was approved as pentobarbital sodium by SAGENT PHARMS INC on May 23rd, 2016.

  Start Trial

Summary for SODIUM PENTOBARBITAL
Drug patent expirations by year for SODIUM PENTOBARBITAL

US Patents and Regulatory Information for SODIUM PENTOBARBITAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anabolic SODIUM PENTOBARBITAL pentobarbital sodium CAPSULE;ORAL 084590-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Parke Davis SODIUM PENTOBARBITAL pentobarbital sodium CAPSULE;ORAL 084156-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Halsey SODIUM PENTOBARBITAL pentobarbital sodium CAPSULE;ORAL 084677-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Wyeth Ayerst SODIUM PENTOBARBITAL pentobarbital sodium CAPSULE;ORAL 083239-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Perrigo SODIUM PENTOBARBITAL pentobarbital sodium CAPSULE;ORAL 084560-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
McKesson
Harvard Business School
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.